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Abstract
Ovarian carcinoma is the leading cause of gynecological malignancy, with the
serous subtype being the most commonly presented subtype. Recent studies
have demonstrated that grade does not yield significant prognostic information,
independent of TNM staging. As such, several different grading systems have
been proposed to reveal morphological characteristics of these tumors, however
each yield different results. To help address this issue, we performed a rigorous
computational analysis to better understand the molecular differences that fun-
damentally explain the different grades and grading systems. mRNA abundance
levels were analyzed across 334 total patients and their association with each
grade and grading system were assessed. Few molecular differences were
observed between grade 2 and 3 tumors when using the International Federa-
tion of Gynecology and Obstetrics (FIGO) grading system, suggesting their
molecular similarity. In contrast, grading by the Silverberg system reveals that
grades 1–3 are molecularly equidistant from one another across a spectrum.
Additionally, we have identified a few candidate genes with good prognostic
information that could potentially be used for classifying cases with similar
morphological appearances.
Introduction
Ovarian cancer is one of the most lethal gynecological
cancers and is the fifth most common cause of cancer
death in North America [1]. Many subtypes of epithelial
ovarian carcinoma exist including the serous, clear cell,
endometrioid, and mucinous subtypes [2]. There are sub-
stantial differences in genetic risk factors and somatic
mutation profiles between each of these subtypes. The
majority of ovarian carcinomas that are presented at the
clinic correspond to cancer of the serous subtype [3].
Accurate diagnosis and prognosis are critical for disease
management and therapeutics. To aid this, histopatholog-
ical grade is intended to provide additional information
to a nominal diagnostic category; information which
should have prognostic or therapeutic implications. How-
ever, if designation of a tumor to a specific diagnostic
category conveys sufficient information, grading is not
necessary [4, 5]. Histologic reporting of ovarian carcino-
mas has traditionally required assessment of both cell type
and grade. A number of grading systems exist, including
the Silverberg [6], the International Federation of Gyne-
cology and Obstetrics (FIGO) [7], the World Health
Organization (WHO) [8], and the Gynecologic Oncology
Group (GOG) systems [9]. Each grading systems employs
a different scheme, but most are ternary systems stratify-
ing ovarian serous carcinomas into well, moderately, and
poorly differentiated categories. These ternary grading sys-
tems imply a progressive deterioration in differentiation,
and the Silverberg, FIGO, and WHO systems are
56 ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of
the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Cancer Medicine
Open Access
“universal” in the sense that they can be applied regard-
less of cell type [6]. The GOG system, by contrast, is cell-
type–specific, requiring initial assessment of cell type with
subsequent application of a histotype–specific grading sys-
tem [9].
A two-tier system has been recently proposed, and is
suggested to be superior to the above three-tier systems
[10]. Tumors classified into low- or high-grade ovarian
carcinoma have distinct histological, molecular, and clini-
cal profiles. Molecularly, low-grade serous carcinomas
generally have low levels of chromosomal instability and
carry frequent mutations in KRAS, BRAF, and ERBB2,
while high-grade serous carcinomas tend to have high lev-
els of chromosomal instability and frequently show muta-
tions in TP53 [10]. Histologically, low-grade ovarian
serous carcinoma generally has a micropapillary-rich
growth pattern, while high-grade ovarian serous carci-
noma adapts a large papillae and glandular pattern with
infrequent micropapillary growth. Tumors classified by
this binary grading system demonstrate diverse survival
profiles, with median survival of 4.2 years in patients with
low-grade tumors and 1.7 years in those with high-grade
tumors [10, 11].
Classification of some grade 2 tumors (characterized as
having larger nuclei and nucleoli, coarser chromatin, and
more mitotic activity) has been challenging [10, 11]. One
of the significant aspects of accurate pathological grading
is its association with treatment options. Since low- and
high-grade tumors exhibit differences in proliferation rate,
it is possible that they respond to chemotherapy differ-
ently [10]; hence the accurate pathological grading of a
tumor is exceptionally important. Previous clinical studies
demonstrated that low-grade serous carcinoma were not
as responsive to traditional chemotherapeutic agent, such
as taxane and platinum, in comparison to high-grade car-
cinomas [12].
Although such grading lacks prognostic significance
and clinical reproducibility, it remains possible that
tumor grade can accurately capture some underlying
molecular characteristics of the tumor that are not
reflected through other measures [11]. In fact, previous
work using principal component analysis (PCA) on
mRNA abundance profiles to dichotomize tumors into
low- and high-grade groups [13]. This strongly suggests
the presence of clear molecular differences between
tumors of different grades. To test this hypothesis, we
surveyed the serous ovarian cancer transcriptome and
identified genes associated with well, moderately, and
poorly differentiated tumors as established by the FIGO
and Silverberg systems. We assessed the association of
these genes with patient survival and considered their
involvement with known biomolecular pathways.
Materials and Methods
Patient cohort
Raw microarray data and patient-level annotation from
multiple datasets were used [14–17]. Raw data were
assessed for distributional homogeneity. Redundant sam-
ples were identified by comparing raw array data (CEL
files) across datasets and were excluded from the study.
In addition, the large The Cancer Genome Atlas (TCGA)
dataset [18] was not included in this study as it did not
annotate which grading system was used, and the project
spanned several years of reporting, hence it was likely that
both grading systems were used at some centers. The
remaining raw data were then loaded into R statistical
environment (v2.15.3) using the affy package (v1.36.1).
Probes were remapped to Entrez Gene IDs using the fol-
lowing packages: hgu95av2hsentrezgcdf v16.0.0, hgu133-
plus2hsentrezgcdf v16.0.0, hgu133ahsentrezgcdf v16.0.0.
Data were preprocessed using the RMA algorithm [19]
and associated with published patient annotation, includ-
ing grade, primary tumor site, stage, survival status, and
survival time. Patients that underwent neoadjuvant treat-
ment prior to surgery were excluded from this analysis. A
total of four datasets were employed: for each, the num-
ber of patients included, number of genes evaluated, and
other clinical covariates are provided in Table 1. To
increase statistical power, we combined datasets based on
their grading systems (i.e., datasets using the FIGO grad-
ing system were pooled, as were datasets using the Silver-
berg grading system). We first applied a Y-chromosome-
based filtering method to remove probes which displayed
intensity levels similar to or below a threshold. Intensity
levels detected for chromosome Y-specific probes in
female samples are deemed to be background noise [20].
To further minimize or remove nonbiological technical
variations, such as batch effects caused by combining
multiple datasets together, we applied ComBat using R
package (sva_v3.4.0) to the pooled mRNA abundance lev-
els [21]; the sources of data were treated as batch effects
and tumor grade was used as a covariate in ComBat.
Differential expression analysis
To identify which genes were differentially expressed between
different tumor grades, we analyzed the gene expression val-
ues across patient groups using a per-gene multivariate linear
model. The expression levels were modeled as a function of
tumor grades and the dataset of origin as:
Yi¼Ai;0þAi;1IðGrade¼2Þ
þAi;2IðGrade¼3ÞþAi;3 IðDataset¼2Þþei
(1)
ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 57
C. Q. Yao et al. Transcriptomic Profile of Ovarian Cancer Grading
where Yi is the normalized mRNA abundance levels for
the ith gene, Ai,0 represents the baseline expression of
the ith gene, Ai,1 and Ai,2 are the coefficients of tumor
grade for the ith gene, Grade is an indicator where
0/1 represents the different grades, Ai,3 is the coeffi-
cient of dataset for the ith gene, Dataset is an indica-
tor where 1/2 indicates the different datasets, ei is an
error term.
To test whether the difference in mRNA abundance
levels between different tumor grade groups was statisti-
cally significant from zero, a model-based t-test was used
(mRNA abundance levels from patients with grade 1
tumors were compared to those with grade 2 tumors and
so forth). P-values were adjusted for multiple testing
using false-discovery rate (FDR) correction [22]. Coeffi-
cients representing the change in mRNA abundance levels
between each comparison were adjusted with an empirical
Bayes moderation of the standard error [23]. Genes below
a FDR threshold of 10% (i.e., Padjusted < 0.1) were
deemed significant; this threshold was chosen as the num-
ber of differentially expressed genes started to plateau
across all group comparisons at thresholds lower than this
value.
Data visualization
Unsupervised machine learning was performed using divi-
sive hierarchical clustering with the Divisive Analysis
Clustering (DIANA) algorithm and Pearson’s correlation
as a similarity metric. We performed variance filtering on
mRNA abundance levels with a threshold of 1. This filter-
ing removed genes that were not differentially expressed.
This analysis used the cluster (v1.14.4), lattice (v0.20-15),
and latticeExtra (v0.6-24) packages from R statistical envi-
ronment (v2.15.3). Venn diagrams were created using the
VennDiagram package (v1.6.0) [24]. An FDR-adjusted
P-value (Padjusted) sensitivity plot was generated by plot-
ting the number of genes altered at every Padjusted value
cut-off, with P-value thresholds spanning the range from
Padjusted = 1 9 10
6 to Padjusted = 0.5.
Pathway analysis
To identify pathways or biological functions associated
with differentially expressed genes, we conducted pathway
analysis using GoMiner [25] and Gene Ontology (GO)
annotation [26]. A relaxed Padjusted cut-off of 0.25 was
selected to obtain a list of genes that showed differential
mRNA abundances between tumors of different grades.
GoMiner analysis was run on the 2011-01 database built
with the following settings: 10% FDR threshold, 1000
randomizations, all human databases and look-up
options, the smallest category size for category statistics of
5 and all GO evidence codes, and ontologies.
Survival analysis
To characterize the clinical utility of genes showing differ-
ential expression across tumors from different grades, we
explored the prognostic ability of these genes to accu-
rately predict patient survival. Patients were median-
dichotomized based on mRNA abundance levels of those
genes determined to be differentially expressed between
tumor grades. Median dichotomization was performed
separately for each dataset and a Cox proportional haz-
ards model adjusted for tumor stage was then fit on the
resulting data [27]. Patient survival was modeled as a
function of this group assignment. Survival analysis was
conducted using the survival package (v2.37-4) in the R
statistical environment.
Results
Global patterns of mRNA abundance
Four separate datasets of serous ovarian cancer were com-
piled, providing abundance measurements for 12,080
genes across 334 patients. Each dataset was normalized
independently and then merged into a single dataset. Sur-
rogate-Variable Analysis using the ComBat algorithm was
performed to reduce batch effects (Fig. S1A and B show
Table 1. A list of datasets used in this analysis as well as their summary clinical information.
Datasets
Number
of patients
Number
of genes
Median survival
(years)
Median
age
Median
stage
Median
grade PMID Sources
Berchuck 11 12080 NA 52 I 2 15897565 http://data.cgt.duke.edu/clinicalcancerresearch
Bild 112 12080 2.83 59 III 2 16273092 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE3149
Denkert 68 12080 2.88 NA III 3 19294737 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE14764
Tothill 143 18989 2.42 59 III 3 18698038 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE9899
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strong dataset-specific effects prior to batch-effect
removal).
Hierarchical clustering of mRNA abundance levels
using DIANA revealed minimal molecular differences
based on clinical and technical covariates (grade, using
the FIGO (Fig. 1A) or Silverberg (Fig. 1B) grading
systems, stage, and dataset). This clustering effect was
quantified using the adjusted rand index (ARI; no vari-
able was deemed significant [all variables produced an
ARI close to 0]). This confirms that mRNA abundances
varied substantially even among tumors of the same his-
tologic stage and grade [28].
Genes associated with tumor grade
We then sought to determine the number of genes differ-
entially expressed between tumors of different grades.
Since two different grading systems were used, we
analyzed the FIGO and Silverberg grading systems sepa-
rately using general linear modeling with multiple-testing
correction. Surprisingly, very few genes were differentially
expressed between FIGO grade 2 and 3 tumors, suggest-
ing that these two groups are essentially indistinguishable.
By contrast, FIGO grade 3 and 2 tumors both differed
substantially from grade 1 tumors (Fig. 2A). A slightly
larger number of genes were differentially expressed
between grade 3 and 1 tumors than between grade 2 and
1 tumors (75 vs. 69, respectively, at a 10% FDR cut-off);
these findings were threshold independent. By contrast,
Silverberg grade 1, 2 and 3 tumors differed from one
another in all pair-wise combinations (Fig. 2B). These
results suggest that Silverberg grade 2 tumors (but not
FIGO grade 2 tumors) comprise a molecularly distinct
entity. Table S1 gives the gene-level results of our statisti-
cal modeling for all comparisons.
To determine whether this difference between grading
systems held true at the level of individual genes, we
chose a 10% FDR cut-off to identify differentially
(A) (B)
Figure 1. mRNA abundance levels of high-variance genes. Hierarchical clustering of mRNA abundance levels from ovarian cancer tumors shows
that mRNA abundances are neither associated with clinical covariates (grade, stage) nor dataset of origin. (A) Datasets graded using the FIGO
system (adjusted rand index [ARI] for grade, 0.006 [Grade]; dataset, 0.036; stage, 0.013). (B) Datasets graded using the Silverberg system (ARI
for grade, 0.006; dataset, 0.024; stage, 0.015).
(A) (B)
Figure 2. Adjusted P-value sensitivity analysis. The number of genes that showed differential abundance levels between each grade group
comparison was calculated for different adjusted P-value cut-offs (Padjusted) for both the (A) International Federation of Gynecology and Obstetrics
(FIGO) and (B) Silverberg grading systems.
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expressed genes. For FIGO graded tumors (Fig. 3A), there
were no differentially expressed genes between grades 2
and 3, even at this relaxed significance threshold. By con-
trast, both grade 2 and 3 tumors showed similar differ-
ences relative to grade 1 tumors (57 genes in common).
Alternatively, tumors graded using the Silverberg system
(Fig. 3B) showed a more progressive pattern, where all
genes differing between grades 1 and 2 also differed
between grades 1 and 3. These data are consistent with
the idea that FIGO grades 2 and 3 are molecularly indis-
tinguishable, whereas Silverberg grading represents a spec-
trum of states, and that the two systems are characterized
by distinct molecular features (Fig. 3C). Furthermore, we
found that grade was not associated with molecular sub-
type (Tothill dataset; P = 0.368; Pearson’s Chi-square
test).
Pathway-level differences associated with
tumor grade
To identify the biological pathways altered by or govern-
ing the morphological differences between tumors of
different grades, we performed GoMiner analysis on dif-
ferentially abundant genes at a relaxed FDR cut-off of
25%. At a 1% FDR cut-off, 53 and 137 GO terms were
significantly enriched across the FIGO and Silverberg
datasets, respectively (Fig. 4A). As nine GO terms were
significantly enriched across all comparisons, they were
further explored (Fig. 4B). These terms include key can-
cer-related processes associated with rapid cell division,
including cell cycle regulation and cytoskeletal and spin-
dle organization.
Differentially expressed genes predict
survival
Previously, it was shown that grade did not provide addi-
tional prognostic ability independent of cell type or stage.
To examine whether this was true of our data, we per-
formed survival analysis for each dataset, using grade as
the grouping variable (Fig. S2A, S2B, and S2C for Bild,
Denkert, and Tothill datasets, respectively). We found
that grade did not provide sufficient prognostic ability. As
such, we chose to examine whether genes differentially
(A)
(C)
(B)
Figure 3. Overlap of genes with differential abundance between different grades of tumors. Differentially abundant genes between each pair of
grades were compared for each of the (A) International Federation of Gynecology and Obstetrics (FIGO) and (B) Silverberg grading systems, and
(C) across the entire dataset. (A) For FIGO graded tumors, no genes were differentially expressed between grade 2 and 3 tumors at a threshold of
10% false-discovery rate (FDR) while substantial overlap was observed between grade 3 versus 1 tumors and grade 2 versus 1 tumors. (B) A
progressive pattern was observed for the Silverberg grading system. (C) Distinct groups of differentially abundant genes (at a FDR threshold of
25%) were observed, dependent on grading system used.
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expressed between tumors of different grades carry signifi-
cant prognostic information. To test this effect, we mod-
eled overall survival (OS) as a function of mRNA
abundance levels. As described in the Materials and Meth-
ods section, patients were median-dichotomized to low
and high expression based on the mRNA abundance lev-
els of differentially expressed genes. A list of genes and
their stage-adjusted hazard ratios and Cox proportional
hazards model P-values and q-values (adjusted for multi-
ple testing using FDR) are listed in Table S1. Although
we did not observe enrichment for prognostic informa-
tion in these differentially expressed genes (Table S2), we
did identify six genes (APOBEC3C, C11orf16, C21orf2,
MUC5AC, SRD5A2, and TUBA4B) that showed consistent
prognostic abilities (Fig. S3).
Discussion
Low-grade serous tumors are uncommon, accounting for
less than 10% of ovarian serous carcinomas, and show
morphologic progression from cystadenoma/adenofibro-
ma to borderline serous tumor to micropapillary border-
line tumor and finally to invasive low-grade serous
carcinoma [29]. This histological sequence is mirrored by
progressive allelic imbalances: KRAS, BRAF, and ERBB2
mutations are identified in 2/3 of cases and p53 muta-
tions are rare. In contrast, high-grade serous carcinomas
frequently harbor p53 and BRCA mutations and lack the
characteristic mutations of their low-grade counterparts.
These tumors demonstrate a high level of chromosomal
instability even in early stage cases and the majority likely
arises from tubal intraepithelial carcinoma [30].
From a clinical perspective, patients with low-grade ser-
ous carcinoma are younger (median age at diagnosis 43
vs. 63 years) [31], but are more likely to manifest resis-
tance to standard chemotherapy regimens [32]. The bin-
ary low-/high-grade categories of the Malpica system are
effectively nominal categories reflecting these distinct bio-
logical entities rather than grades of the same tumor [11].
It has recently been questioned whether it is relevant to
subclassify high-grade serous carcinoma into moderately
and poorly differentiated categories.
In a study by Malpica, all Silverberg grade 1 and grade
3 tumors corresponded to low- and high grade, respec-
tively [11] while 82% of Silverberg grade 2 tumors were
high grade. The FIGO grading system was more heteroge-
neous: 97% of FIGO grade 1 was determined to be low
grade, while the remaining 3% (1 case) was high grade.
All FIGO grade 3 cases and 72% of FIGO grade 2 cases
were high grade. Thus, the moderate category in these
two systems seems to constitute a mix of high- and low-
grade cases.
Stratification according to grade should reflect thera-
peutic, prognostic, or biological differences within a nom-
inal diagnostic category. Previous study did not
demonstrate prognostic differences between Silverberg
grade 2 and grade 3 serous carcinomas [33]. It has also
been suggested that further stratification of high-grade
serous carcinomas into FIGO moderately and poorly dif-
ferentiated subsets is not clinically relevant based on simi-
lar TP53 mutation results and drug sensitivities [33].
Vang and colleagues recommended additional molecular
studies comparing morphologic subdivision within the
high-grade category of serous carcinoma [10].
(A)
(B)
Figure 4. Overlap of enriched GO terms between different grading
systems and different tumor grade comparisons. (A) Genes that
showed differential expression at a relaxed P-value threshold of 25%
false-discovery rate (FDR) were used for GoMiner analyses. GO terms
were then filtered based on their FDR values (1% FDR threshold) and
these terms were compared across different grade comparisons. (B) A
total of nine GO terms were commonly enriched across all
comparisons. Gray shaded boxes represent FDR values (darker shade
for increased statistical significance); circle size represents log2
enrichment.
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Our current work indicates that there is no significant
difference in mRNA profiles of FIGO grade 2 and grade 3
ovarian serous carcinomas. In addition we have demon-
strated distinct molecular characteristics between tumors
graded with FIGO and Silverberg systems. Tumors graded
with the FIGO system showed consistent results with
what we would expect from a two-tier system, demon-
strating greater molecular similarity between grade 2 and
3 tumors and more differences with grade 1 tumors.
Results were different for Silverberg graded tumors, where
similar numbers of molecular changes were observed
between each pair of tumor grades. This discrepancy
could in part be explained by the difference in the criteria
used for grading. The FIGO grading system is based pri-
marily on the percentage of solid cell architecture,
whereas Silverberg system is based on the scores of three
components: architecture, degree of nuclear atypia, and
mitotic index [10]. It remains possible that the more
stringent scoring metric employed by the Silverberg sys-
tem produced more biologically relevant results.
A similar analysis has previously been performed by
Meingold-Heerlien and colleagues; 12,500 genes were pro-
filed across tumors from 52 patients, including 44 with
serous carcinomas (G1, n = 7; G2, n = 17; G3, n = 20),
although they did not specify which system was used for
grading [34]. They identified a conspicuous distinction
between low malignant potential (LMP)/G1 tumors and
G2/G3 tumors. Statistical analysis found few differences
between LMP and G1 tumors, but many more between
G2 and G3, and large differences between LMP/G1 and
G2/G3.
The Tothill dataset analyzed in this study was initially
used to identify novel molecular subtypes of high-grade
ovarian serous carcinoma [16]. Tothill and colleagues
identified unique molecular subtypes of high-grade serous
carcinoma—C1 (high stromal response), C2 (high
immune signature), C3 (high protein kinase expression),
C4 (low stromal response), C5 (mesenchymal, low
immune signature) subtypes, and C6 (low grade endo-
metrioid). These molecular subtypes were randomly dis-
tributed between grade 2 and 3 tumors and univariate
analysis showed significant differences in both progres-
sion-free survival (PFS) and OS. Multivariate analysis
showed that the C1 group had a significantly worse out-
come even when considering other known prognostic
indicators such as stage, grade, age, and residual disease
(PFS, P = 0.012; OS, P = 0.034) compared to the other
subsets.
In the current study, no central pathologic review across
the datasets was performed, hence some differences that we
observed might potentially be due to misclassification of
tumor grades; additional studies in consistent cohorts are
needed to further validate the results. Furthermore, work
on the identification of molecular signatures of ovarian
cancer as well as characterization of single nucleotide
variants (SNVs) and copy number aberrations (CNAs)
will also be a valuable follow-up to the current study. As
well, it will add great value if multiple grading systems
are used within a single dataset and molecular differences
assessed between the different systems. Nevertheless, we
have shown in this study that FIGO-graded tumors exhib-
ited great molecular similarities between grade 2 and 3
tumors, whereas Silverberg graded tumors demonstrate
more diverse profiles between differentially graded
tumors. Histologic grade carries clinical utility but more
studies are needed to understand the biological processes
in tumors; nevertheless, these data suggest that a two-tier
grading system may be a preferred scheme for grading
ovarian carcinoma of the serous subtype. This issue
certainly merits additional exploration.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. mRNA abundance levels prior to ComBat
adjustment. mRNA abundance profiles were examined
using DIANA clustering for each of the (A) FIGO and
(B) Silverberg grading systems. Before ComBat, mRNA
abundance levels in FIGO-graded tumors did not demon-
strate strong dataset-specific bias (adjusted Rand
index = 0.03), but expression levels in Silverberg graded
tumors showed distinct patterns between the two datasets
(ARI = 1).
Figure S2. Overall survival outcome. Difference in overall
survival between low-grade (grade 1) and high-grade
(grade 2 and 3) ovarian carcinoma patients was margin-
ally significant for the (A) Bild dataset but was insignifi-
cant for both the (B) Denkert and (C) Tothill datasets,
suggesting that histologic grade as a clinical covariate has
minimal prognostic ability.
Figure S3. Gene-specific survival outcome over time.
Genes that showed consistent differential expression
between grade 2 and 1 tumors and grade 3 and 1 tumors
were assessed for their prognostic ability. Patients were
median-dichotomized into low- and high-expression
groups based on the mRNA abundance levels of these
genes. Hazard ratio (HR) indicates the ratio of hazard
rates between patients with high expression level of a
given gene and those with a low expression level. The
numbers in the bracket following HR denote the 95%
confidence interval for the hazard ratio, which are derived
from the standard deviation of the regression model.
Genes with P ≤ 0.05 (Wald test) demonstrate strong
prognostic ability.
Figure S4. Power calculation in current cohort. Power
calculation for effect sizes ranging from 0 to 3.2 for both
FIGO (left) and Silverberg (right) graded tumors. Dashed
horizontal line represents a threshold of 80% power.
Table S1. A list of differentially expressed genes between
different tumor grades and their prognostic abilities.
Table S2. Proportion of significantly prognostic genes
across different comparison groups.
Table S3. Sample summary broken down by grading sys-
tem and different tumor grades and the statistical power
for each comparison. In datasets graded using the FIGO
system, we have 80% power to detect an effect size of
2.34 for grade 3 versus grade 1 comparison, 2.35 for
grade 2 versus grade 1 comparison, and 0.90 for grade 3
versus grade 2 comparison. Similarly, in datasets graded
using the Silverberg system, we have 80% power to detect
an effect size of 2.22 for grade 3 versus grade 1 compari-
son, 2.31 for grade 2 versus grade 1 comparison, and 0.71
for grade 3 versus grade 2 comparison.
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